THE TAPE

Travere Therapeutics, Inc. Common Stock

$49.70▼ −1.88%
Last close
Relative strength
62RS
of 99, against every stock▼ -23 on the month
Cooling off
Unconfirmed
+4.3%
six months against Pharmaceutical Preparations
52-week range
−27.7%
from the high
$22.59$68.73
Setup
blue skyplayed out
−17.3%
against the pivot at $60.10
No report date on the calendar.
Growth REALProof PENDING
Quarter to Sep 30, revenue +36% on a year ago
11/16 O 50.40 H 51.00 L 49.28 Vol 1.2M
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

RS62
vs pivot−17.30%
Tightening0.81×
Dry-up1.27×
Up/down vol-0.07
From high28%
played out2 of 9checks
Cooling off
Support and resistance
Support below
None within the last 120 sessions
Resistance above
$52.51
+5.7% · tested 6× · last 2 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 5.6 weeks and fell 12% from its ceiling at its deepest. The pivot is $60.10, and the stock closed 17.3% below it. Its relative strength rating is 62.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against its industry
-4.1%
Three months against its industry
-10.1%
Six months against its industry
+4.3%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Also on
Peers
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 6.6% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$651.0M
+36.2% year on year
Operating margin
-20.5%
Net margin
-18.7%
Free cash flow
$176.6M
3.8% of market cap
Price to sales
7.20×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 2
Key takeaway
Growth with the cash to show for it: the quarter confirms the thesis.
Revenue
$224.6M
+32.4% QoQ · +36.2% YoY
Gross margin
—
Net income
−$52.3M
Loss
Free cash flow
$98.2M
Cash generating

What the numbers say

  • Good: Revenue +36.2% year over year, +32.4% on the quarter
  • Weak: Net loss $52M, wider than $35M last quarter
  • Good: Cash generating: operating cash flow $98M, free cash flow $98M
  • Good: Share count -7.8% in a year: buying back
  • Good: Net cash $124M · cash $124M
Revenue by quarter
Free cash flow
Net income
shares -7.8% in a year · net cash $123.5M

What is not obvious

  • Weak: Interest $2M a quarter against an operating loss: the debt is carried by the balance sheet, not operations
Final read
Growth: REAL · Economic proof: PENDING
Key question: Can the growth turn into durable profit and cash after its costs and financing?
The next test is operating profit: net loss $52M, wider than $35M last quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 3 of 46 tracked funds at the end of Q3 2026.

Last quarter: 3 trimmed.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
GappedTape · 2026-11-06
-6.8%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-05
+6.1%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Closed below its 20- and 50-day on heavy volumeTape · 2026-11-04
below 20d & 50d on 4.5x volume at 49.41
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).
Unusual volumeTape · 2026-11-04
9.9 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Reported resultsFiling · 2026-11-03
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Earnings comingEvent · 2026-10-21
reports 2026-10-22
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
Earnings date movedEvent · 2026-10-15
2026-10-22 -> 2026-10-28
No measurable effect: stocks behave like random ones over the next three sessions (2,989 cases over 51 nights).
Several insiders soldInsider · 2026-10-15
7 insiders sold $64,990,221
No measurable effect: stocks behave like random ones over the next three sessions (653 cases over 60 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
51
$80,854,200 total

Sold: Dube Eric M, Heerma Peter, ROTE WILLIAM E., Inrig Jula, REED ELIZABETH E, Cline Christopher R., Calvin Sandra, Meckler Jeffrey A, LYONS GARY A, Coughlin Timothy, Baynes Roy D..

Not counted above: 29 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-10-15 Dube Eric M · CHIEF EXECUTIVE OFFICER, Directoroption exercise43,735$1,175,597
2026-10-15 Dube Eric M · CHIEF EXECUTIVE OFFICER, Directoroption exercise200,000$1,786,000
2026-10-15 Dube Eric M · CHIEF EXECUTIVE OFFICER, Directorsell128,065$6,783,244
2026-10-15 Dube Eric M · CHIEF EXECUTIVE OFFICER, Directorsell37,270$2,020,023
2026-10-15 Dube Eric M · CHIEF EXECUTIVE OFFICER, Directorsell78,400$4,313,403
2026-09-17 Heerma Peter · EVP, CHIEF COMMERCIAL OFFICERoption exercise8,282$185,517
2026-09-17 Heerma Peter · EVP, CHIEF COMMERCIAL OFFICERsell8,282$538,917
2026-09-17 Dube Eric M · CHIEF EXECUTIVE OFFICER, Directoroption exercise108,493$2,532,227

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What lines up

2 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy2
Buy12
Hold1
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray
6w · 12%

The most recent of 3 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Travere Therapeutics, Inc. Common Stock (TVTX) — The Tape